NCT07521852 2026-04-13
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TaiRx, Inc.
Phase 2 Recruiting
Clinical Trials
8 trialsNCT07018063 2025-06-12
YOUNG-NEOS
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT05572463 2022-11-18
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Withdrawn
NCT02937116 2022-10-14
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT05322187 2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3 Unknown
NCT04400851 2020-09-03
Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors
Sun Yat-sen University
Phase 1 Unknown
NCT04371796 2020-05-01
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT03874000 2019-03-19
SMART
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown